Further probing for associations across TCAF2 levels and overall survival (OS) within TCGA data indicated that regardless of whether the diagnosis was a glioma, LGG, or GBM, cases having upregulated TCAF2 expression had shorter OS in comparison with patients having lower TCAF2 expression (Fig. 1D-F). This evidence concerns the gene TCAF2 and central nervous system cancer.